Idorsia raises Sfr505m through share sale and CB to fund clinical trialsIdorsia, the Swiss biopharmaceutical company, has raised Sfr505m to finance advanced clinical trials after a simultaneous share and convertible bond sale overnight in Zurich.

Idorsia, the Swiss biopharmaceutical company, has raised Sfr505m to finance advanced clinical trials after a simultaneous share and convertible bond sale overnight in Zurich.http://www.globalcapital.com/article/b190wjml4wq3vb/idorsia-raises-sfr505m-through-share-sale-and-cb-to-fund-clinical-trials[Collection]